N/A N=447 Multidisciplinary Support Program in Chronic Hepatitis C
Hepatitis C, Chronic
Primary: Adherence to Treatment — 116; 155; 124 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment
Hepatitis C · Depression · PTSD
Primary: Sustained Viral Response (SVR) — 30; 12.8 percentage of Participants — p=0.07
N/A N=138 Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C
Hepatitis C · Alcohol Abuse
Primary: Change in Days of Unhealthy Alcohol Consumption — 5.46; 7.16; 2.72; 5.56 Unhealthy drinking days in last 30
N/A N=139 Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients
Alcohol Dependence · Chronic Hepatitis C
Primary: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. — 14.88; 21.41 Standard Alcohol drinks
N/A N=568 Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252)
Hepatitis C, Chronic · Hepacivirus
Primary: Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared…
Phase 4 N=197 Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Chronic Hepatitis C · Genotype 1
Primary: Treatment Duration Compliance Rate — 85.4; 83.8 Percentage of compliance — p=0.4864
N/A N=309 Hepatitis C Translating Initiatives for Depression Into Effective Solutions
Hepatitis C · Depression
Primary: Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 11; 7 participants
N/A N=46 HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
Hepatitis C · Alcohol Use Disorder
Primary: Changes in Neuropsychological Assessment Battery (NAB) Attention Module Scores — 10.99; 0.31; 6.35 Units on a scale
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
N/A N=31 Understanding and Intervening With Heavy Drinking Among Patients With HIV and HCV
Alcohol Use Disorder · HIV/AIDS · Hepatitis C
Primary: Mean Drinks Per Drinking Day Measured Using Timeline Follow Back (TLFB) at 60 Days. — 2.61; 5.49 Drinks per drinking day
Phase 4 N=180 Baclofen to Reduce Alcohol Use in Veterans With HCV
Hepatitis C · Alcohol Use Disorders
Primary: Number of Drinking Days in the Past Two Weeks — 8.6; 8.9; 6.8; 7.1 Number of Drinking Days/2 weeks — p=<0.01
N/A N=21 Effective Treatment of Hepatitis C in Substance Users
Hepatitis C · Opiate Dependence
Primary: Number of Participants With a Sustained Virologic Response (SVR) — 7; 1 participants
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken
N/A N=40 Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications
Adherence
Primary: Use of Portal724-MEMS Service on Medication Adherence in the Treatment of Hepatitis C in Patients, Defined as Compliance to Regimen 95% of the Time. — 19; 18…
N/A N=364 An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
Hepatitis C
Primary: Sustained Virologic Response Rates — 29; 14 participants
N/A N=348 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Hepatitis C, Chronic
Primary: Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin — 56; 150 participants
N/A N=294 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Are Triple-80 Compliant — 183 Participants
N/A N=134 Hepatitis C Self-Management
Hepatitis C · Chronic Disease
Primary: Quality of Well-being Scale - Self-Administered (QWB-SA) — .534; .501; .600; .504 units on a scale
N/A N=134 Records for Alcohol Care Enhancement
Alcohol Use Disorder (AUD)
Primary: Percent of New Alcohol Use Disorder (AUD) Diagnosis Episodes That Meet Criteria for AUD Treatment Engagement Among Patients With a New AUD Diagnosis Who Are Empaneled to…
N/A N=746 Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
Hepatitis C · Chronic Hepatitis C
Primary: Number of Participants With Biometrical Adherence to Therapy — 406; 415; 413 Participants
N/A N=258 Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181)
Hepatitis C, Chronic
Primary: Percentage of Participants With Relapse At 24 Weeks After the End Of Treatment (EOT) — 13.65 Percentage of participants
N/A N=130 Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)
Hepatitis C, Chronic · Genotype 1 · HCV-1
Primary: Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores — 87.27; 87.33; -1.56; 81.71 score on a scale
N/A N=21 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal
Hepatitis C
Primary: Attributes of Treatment Experience — 14; 15; 7; 9 participants
N/A N=755 Patient-Centered Models of HCV Care for People Who Inject Drugs
Hepatitis C · Medication Adherence
Primary: Sustained Viral Response (SVR) — 226; 236 participants
N/A N=11 Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs
Hepatitis C · Medication Adherence
Primary: HCV Treatment Adherence — 83; 100; 88 percent of medication taken
N/A N=285,304 Sustaining Patient-centered Alcohol-related Care
Alcohol, Drinking · Alcohol Use Disorder
Primary: Brief Alcohol Counseling Rate — 57; 11 participants per 10,000 with visits — p=<.001
Phase 4 N=11 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic
Hepatitis C, Chronic · Hepatitis C · Opiate Dependence
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment (SVR-12) — 7 Participants
N/A N=20 VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C
Patient Adherence, Chronic Hepatitis C, Alcohol-related Disorders
Primary: Treatment Completion — 15 Participants
N/A N=2,430 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1) — 685 participants
N/A N=294 Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings
HIV · Alcohol Use · Medication Adherence
Primary: Viral Load — 3.1; 1.8; 1.8; 2.6 Log-transformed copies per. milimeter — p=0.39